Makary’s FDA agenda, amylin in obesity and life after DEI

Pending confirmation for new head of FDA will cap a tumultuous transition

The almost certain confirmation of Marty Makary as FDA commissioner this month will cap a transition marked by internal upheaval and political infighting. On the latest BioCentury This Week podcast, BioCentury’s editors discuss Thursday’s confirmation hearing for President Donald Trump’s pick to lead the agency and Makary's hints at what we can expect from his agenda. 

The editors also discuss whether the advantages of amylin agonists could help the therapies outshine GLP-1 in obesity, why the latest weight loss data from CagriSema weighed on shares of Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO), and a call to deliver on the meritocracy ideal, now that DEI is dead.